| Name | Title | Contact Details |
|---|
A large molecule CRO combining world-class protein chemistry expertise, integrated large molecule analytical services, and coagulation reagents for biopharma R&D.
JSR Life Sciences is a business unit of JSR Corporation, a global company built on more than 50 years of performance material expertise and it began research in the life sciences field more than 30 years ago. We are continually developing highly functional materials and products to meet the current and future needs of the growing biotechnology industry. Using a variety of integrated, leading-edge technologies, JSR Life Sciences provides materials that contribute to the manufacturing process of biopharmaceuticals, life science research applications, in vitro diagnostics and medical devices. JSR Life Sciences has offices, laboratories and manufacturing facilities in Tokyo and Tsukuba (JP), Sunnyvale (CA, USA), Leuven (BE) and Beijng (CN). We are a part of the JSR Corporation, an international company employing over 6’000 people worldwide and being a leading materials supplier in a variety of technology driven markets. JSR Corporation`s global network is headquartered in Tokyo (Japan) and has factories and offices all over the world. As a research-oriented organization, JSR Corporation pursues close collaborations with leading innovators in a number of industries that are key to the present and future welfare of human society: life sciences, elastomers, electronic materials, energy storage, display materials and optical materials.
Coastal Pharma Group is a Oxnard, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs
Curve Biosciences (“Curve”), a company bringing precision to chronic disease care, creates products targeting biological changes in tissues that result in the development and progression of chronic diseases. Curve`s Chronic Disease Tissue Atlas (CDTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies. Curve is focused on first commercializing its best-in-class blood tests for the $30 billion market of chronic liver diseases while using CDTA to find biomarkers and targets for other conditions.